Video Reports

For patients with melanoma, hope lies at the dermatology unit of Institut Gustave Roussy, located in the Paris suburb of Villejuif, France, and considered one of the world’s foremost cancer research centers.

Caroline Robert, MD, PhD, head of the Dermatology Unit at the Institut Gustave-Roussey, co-director of the Melanoma Research Unit at INSERM 981 Paris-Sud University, explains why patients with melanoma and brain metastases were excluded from a trial evaluating the efficacy of dabrafenib (Tafinlar) plus trametinib (Mekinist).

Keith T. Flaherty, MD, a professor of medicine at Harvard Medical School, director of the Henri and Belinda Termeer Center for Targeted Therapy, and director of clinical research at Massachusetts General Hospital, discusses the combination regimens and the potential role for a 3-drug regimen as treatment for patients with melanoma.

Hussein A. Tawbi, MD, PhD: The choice of what to use first for our patients with metastatic melanoma in the first-line setting is complex because we have effective immunotherapy and effective targeted therapy, and we’ve never had them compared head-to-head.